Global Cyclodextrins in Pharma Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Cyclodextrins in Pharma Market Overview

The Cyclodextrins in Pharma Market was valued at USD 316.32 million in 2025 and is projected to reach USD 432.90 million by 2033, growing at a CAGR of 4.00% from 2026 to 2033. The market is witnessing steady growth driven by increasing adoption of cyclodextrins as excipients in advanced drug formulations, rising demand for solubility enhancement of poorly water-soluble drugs, and expanding use in controlled and targeted drug delivery systems.

The growing focus on improving bioavailability and stability of active pharmaceutical ingredients (APIs), combined with rapid advancements in formulation science and nanotechnology-based drug delivery, is significantly boosting the use of cyclodextrins across the pharmaceutical industry. In addition, increasing R&D investments by pharmaceutical companies, along with expanding applications in oral, injectable, and topical drug formulations, are further supporting market expansion, particularly in novel therapeutics and complex molecule development.

Key Market Trends & Insights

• North America dominated the Cyclodextrins in Pharma Market with the largest revenue share of 36.28% in 2025, supported by strong pharmaceutical R&D activity, high adoption of advanced drug delivery systems, and presence of major specialty excipient manufacturers.
• The 2-Hydroxypropyl-β-Cyclodextrin segment led the market with a 38.47% share in 2025, driven by its superior solubilizing ability, improved safety profile, and wide regulatory acceptance in injectable and oral drug formulations.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 6.9% from 2026 to 2033, fueled by expanding generic drug production, rising pharmaceutical R&D investments, and growing healthcare infrastructure in China, India, and South Korea.
• Sulfobutylether β-Cyclodextrin are the fastest-growing type, projected to register a CAGR of 6.8%, reflecting the surge in demand for enhanced safety profile and superior complexation efficiency for injectable drugs.
• The Cyclodextrin Conjugates segment dominated the structure category with a 35.62% revenue share in 2025, led by their strong ability to chemically link with active pharmaceutical ingredients for improved stability and controlled release.
• Hydrophilic accounted for 57.84% of the market, preferred by its widespread use in enhancing solubility and bioavailability of poorly water-soluble drugs.
• The Liquid segment is the fastest-growing form category, with a CAGR of 7.0%, driven by the increasing demand for injectable and intravenous formulations.

Market Size & Forecast

• Global Market Value (2025): USD 316.32 Million
• Expected Market Value (2033): USD 432.90 Million
• Forecast CAGR (2026–2033): 4.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Cyclodextrins in Pharma Market Segmentation

Cyclodextrins in Pharma Market Trends

Trend: Expansion in Advanced Drug Delivery & Formulation Technologies

Pharmaceutical companies are increasingly incorporating cyclodextrins to enhance solubility, stability, and bioavailability of poorly water-soluble drugs across oral, injectable, and topical formulations. The growing shift toward complex molecules, including biologics and lipophilic APIs, is accelerating demand for inclusion complexes that improve drug performance without altering therapeutic efficacy. Continuous innovation in nanotechnology-based delivery systems and controlled-release formulations is further strengthening the role of cyclodextrins in next-generation drug development platforms. For instance, injectable itraconazole and other antifungal formulations increasingly use hydroxypropyl-β-cyclodextrin to improve aqueous solubility and clinical usability.

Cyclodextrins in Pharma Market Dynamics

Key Market Driver: Rising Demand for Solubility Enhancement of Poorly Soluble Drugs

The growing prevalence of low-solubility active pharmaceutical ingredients is significantly driving the adoption of cyclodextrins as enabling excipients in modern drug formulations. Pharmaceutical manufacturers are increasingly relying on cyclodextrin complexes to improve absorption rates, enhance bioavailability, and ensure consistent therapeutic outcomes in both generic and innovative drug pipelines. This demand is further reinforced by expanding R&D investments focused on reformulating existing drugs and improving patient compliance through more effective dosage forms. For instance, cyclodextrin-based reformulations of anticancer and antifungal drugs are widely used to improve intravenous delivery efficiency and reduce toxicity concerns.

Key Restraint/Challenge: High Cost and Regulatory Complexity of Pharmaceutical-Grade Cyclodextrins

A major restraint in the cyclodextrins in pharma market is the high production cost and stringent regulatory requirements associated with pharmaceutical-grade excipients, particularly modified cyclodextrins. The purification processes required to meet injectable and high-purity oral formulation standards significantly increase manufacturing complexity and overall cost, limiting adoption among price-sensitive generic drug producers. In addition, varying regulatory approvals across regions create barriers for large-scale commercialization and slow down product development cycles. For instance, regulatory scrutiny surrounding β-cyclodextrin derivatives in parenteral applications has led to extended approval timelines in several international markets.

Key Market Opportunity: Expansion in Targeted Drug Delivery and Novel Therapeutic Applications

The increasing focus on precision medicine and advanced drug delivery systems is creating strong opportunities for cyclodextrins in targeted and controlled-release formulations across oncology, neurology, and rare disease therapeutics. Their ability to form inclusion complexes with hydrophobic drugs enables improved site-specific delivery, reduced toxicity, and enhanced therapeutic efficiency, making them highly suitable for next-generation specialty medicines. Growing adoption in reformulating existing drugs and enabling new molecular entities is further expanding commercial potential across both branded and generic pharmaceutical segments. For instance, cyclodextrin-based complexes are increasingly being explored in anticancer drug delivery systems such as paclitaxel formulations to improve solubility and reduce formulation-related adverse effects.

Cyclodextrins in Pharma Market Scope

The cyclodextrins in pharma market is segmented on the basis of type, structure, nature, form, application, therapeutics area, and distribution channel.

• By Type

On the basis of type, the Cyclodextrins in Pharma Market is segmented into β-Cyclodextrin, 2-Hydroxypropyl-β-Cyclodextrin, α-Cyclodextrin, γ-Cyclodextrin, Randomly Methylated β-Cyclodextrin, Sulfobutylether β-Cyclodextrin, and 2-Hydroxypropyl-γ-Cyclodextrin. The 2-Hydroxypropyl-β-Cyclodextrin segment dominated the market with a 38.47% share in 2025, owing to its superior solubilizing ability, improved safety profile, and wide regulatory acceptance in injectable and oral drug formulations. It is extensively used in antifungal, anticancer, and cardiovascular drugs to enhance bioavailability of poorly soluble APIs. Strong compatibility with both hydrophilic and lipophilic compounds makes it highly versatile in pharmaceutical applications. Its established clinical use and commercial availability further strengthen its dominance across global markets. Increasing adoption in parenteral formulations continues to reinforce its leadership position.

The Sulfobutylether β-Cyclodextrin segment is expected to register the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by its enhanced safety profile and superior complexation efficiency for injectable drugs. It is widely used in parenteral formulations due to low toxicity and high aqueous solubility characteristics. Growing demand for advanced injectable therapies, especially in oncology and critical care, is accelerating adoption. Pharmaceutical companies are increasingly using it in reformulations of existing drugs to improve stability and reduce side effects. Regulatory approvals for new drug applications are further supporting market penetration. Expanding biologics and specialty drug pipelines are also boosting demand for this derivative.

• By Structure

On the basis of structure, the market is segmented into cyclodextrin conjugates, mucoadhesive drug carriers, cyclodextrin associates, amphiphilic cyclodextrins, and others. The Cyclodextrin Conjugates segment dominated the market with a 35.62% share in 2025, driven by their strong ability to chemically link with active pharmaceutical ingredients for improved stability and controlled release. These conjugates enhance drug targeting efficiency and reduce degradation in biological environments. They are widely used in oncology and chronic disease treatments where sustained release is critical. Increasing R&D in advanced drug delivery systems is further supporting their adoption. Their ability to improve pharmacokinetics makes them highly valuable in novel drug formulations. Strong presence in patented drug technologies reinforces their market leadership.

The Amphiphilic Cyclodextrins segment is projected to be the fastest growing at a CAGR of 7.1% from 2026 to 2033, due to their unique ability to interact with both hydrophilic and lipophilic drug molecules. This dual affinity enables improved membrane permeability and targeted drug delivery. They are increasingly used in nanomedicine and advanced therapeutic systems. Growing focus on precision medicine and intracellular drug delivery is driving demand. Pharmaceutical innovation in cancer and neurological treatments is accelerating adoption. Rising investment in nanotechnology-based drug carriers is further supporting segment growth.

• By Nature

On the basis of nature, the market is segmented into hydrophilic and hydrophobic cyclodextrins. The Hydrophilic segment dominated the market with a 57.84% share in 2025, due to its widespread use in enhancing solubility and bioavailability of poorly water-soluble drugs. Hydrophilic cyclodextrins are highly preferred in oral and injectable formulations because of their excellent compatibility with aqueous systems. They play a key role in improving drug dissolution rates and absorption efficiency. Their safety profile and regulatory acceptance further support extensive pharmaceutical usage. Increasing demand for liquid and injectable formulations continues to strengthen this segment. Strong utilization in generic and branded drug manufacturing reinforces its dominance.

The Hydrophobic segment is expected to grow fastest at a CAGR of 6.6% from 2026 to 2033, driven by increasing use in controlled-release and targeted drug delivery systems. These cyclodextrins are gaining traction in lipid-based and sustained-release formulations. Their ability to encapsulate hydrophobic drugs improves stability and therapeutic efficiency. Growing research in cancer and CNS drug delivery is boosting adoption. Advancements in modified cyclodextrin chemistry are further enhancing performance. Expanding applications in specialty therapeutics are accelerating segment growth.

• By Form

On the basis of form, the market is segmented into solid and liquid. The Solid segment dominated the market with a 64.18% share in 2025, driven by ease of handling, long shelf life, and widespread use in tablet and capsule formulations. Solid cyclodextrins are preferred in large-scale pharmaceutical manufacturing due to stability and cost-effectiveness. They are extensively used in oral solid dosage forms for improving drug solubility. Strong compatibility with dry blending and granulation processes supports their dominance. Increasing production of generic solid dosage drugs further strengthens this segment. Pharmaceutical manufacturing scalability continues to reinforce its leadership.

The Liquid segment is expected to grow fastest at a CAGR of 7.0% from 2026 to 2033, driven by increasing demand for injectable and intravenous formulations. Liquid cyclodextrins are widely used in hospital-based therapies requiring rapid drug delivery. They offer improved flexibility in formulation of unstable or poorly soluble APIs. Growing adoption in critical care and oncology treatments is boosting demand. Advances in sterile formulation technologies are further supporting growth. Expanding biologics and parenteral drug pipelines are accelerating segment expansion.

• By Application

On the basis of application, the market is segmented into drug solubility and dissolution, drug bioavailability, drug safety, drug stability, and others. The Drug Solubility and Dissolution segment dominated the market with a 41.76% share in 2025, driven by increasing need to improve performance of poorly water-soluble drugs. Cyclodextrins are widely used to form inclusion complexes that enhance dissolution rates and absorption. Pharmaceutical companies rely heavily on this application in both new drug development and reformulation strategies. Rising prevalence of poorly soluble APIs in drug pipelines strengthens demand. Strong adoption across oral and injectable formulations reinforces dominance. Continuous innovation in solubility enhancement technologies supports market leadership.

The Drug Bioavailability segment is expected to grow fastest at a CAGR of 6.9% from 2026 to 2033, driven by increasing focus on improving therapeutic efficiency of existing drugs. Cyclodextrins help enhance systemic absorption and reduce dose requirements. Growing emphasis on patient compliance and reduced side effects is boosting adoption. Pharmaceutical R&D is increasingly targeting bioavailability optimization in reformulations. Expanding use in oncology and CNS drugs is further supporting growth. Advances in nanocarrier systems are accelerating segment expansion.

• By Therapeutics Area

On the basis of therapeutics area, the market is segmented into pain management, cardiovascular diseases, behavioral disorder, cancer therapy, rheumatoid arthritis, epilepsy, Niemann-Pick Disease Type C (NPC), and others. The Cancer Therapy segment dominated the market with a 39.28% share in 2025, driven by high use of cyclodextrins in solubilizing and delivering anticancer drugs. Many chemotherapeutic agents require formulation enhancement due to poor solubility. Cyclodextrins improve drug stability and reduce toxicity in cancer treatments. Increasing global cancer burden is further strengthening demand. Strong pipeline of oncology drugs supports continued dominance. Pharmaceutical innovation in targeted cancer therapies reinforces this segment.

The Niemann-Pick Disease Type C (NPC) segment is expected to grow fastest at a CAGR of 7.3% from 2026 to 2033, driven by rising use of cyclodextrin-based therapies in rare disease treatment. Hydroxypropyl-β-cyclodextrin is being actively studied for its cholesterol-clearing properties in NPC management. Growing orphan drug development programs are supporting research and adoption. Regulatory incentives for rare disease treatments are accelerating innovation. Increasing clinical trials are expanding therapeutic applications. Strong unmet medical need is driving rapid segment growth.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. The Direct Tender segment dominated the market with a 61.43% share in 2025, driven by bulk procurement by pharmaceutical companies, hospitals, and research institutions. This channel ensures cost efficiency and consistent supply of high-purity cyclodextrins. Strong relationships between manufacturers and large-scale buyers support dominance. It is widely used in institutional and government healthcare procurement systems. Increasing demand from pharmaceutical production facilities further strengthens this segment. Reliable supply chain agreements reinforce its leadership position.

The Retail Sales segment is expected to grow fastest at a CAGR of 7.2% from 2026 to 2033, driven by increasing availability of specialty excipients through distributors and chemical suppliers. Small and mid-sized pharmaceutical companies are increasingly sourcing through retail channels. Growing demand from research laboratories and academic institutions is boosting adoption. Expanding online chemical distribution platforms are further supporting growth. Flexibility and lower entry barriers make this channel attractive. Increasing global R&D activity continues to accelerate expansion.

Cyclodextrins in Pharma Market Regional Analysis

North America dominated the Cyclodextrins in Pharma Market with the largest revenue share of 36.28% in 2025, supported by strong pharmaceutical R&D activity, high adoption of advanced drug delivery systems, and presence of major specialty excipient manufacturers. The region also benefits from high adoption of innovative drug delivery systems, extensive use of cyclodextrins in injectable and oral formulations, and a well-established regulatory framework supporting excipient innovation. Increasing demand for solubility enhancement of poorly water-soluble drugs and strong investments in oncology and specialty therapeutics continue to strengthen North America’s leadership position in the global market.

U.S. Cyclodextrins in Pharma Market Insight

The U.S. cyclodextrins in pharma market is witnessing strong growth due to rising investments in advanced drug formulation technologies, expanding R&D in specialty therapeutics, and increasing demand for solubility enhancement solutions. The country’s well-established pharmaceutical industry, along with widespread adoption of cyclodextrins in injectable, oral, and oncology drug formulations, is driving market expansion across commercial and clinical applications. In addition, growing focus on biologics development, precision medicine, and reformulation of existing drugs is accelerating cyclodextrin adoption across pharmaceutical manufacturers and research institutions.

Europe Cyclodextrins in Pharma Market Insight

The Europe cyclodextrins in pharma market remains a major contributor to global revenue, driven by strong regulatory support for excipient innovation, advanced pharmaceutical manufacturing capabilities, and high demand for improved drug delivery systems. The widespread use of cyclodextrins in injectable and controlled-release formulations is supporting market expansion across oncology, cardiovascular, and specialty drug segments. Increasing investments in pharmaceutical R&D, coupled with strict quality standards and a highly developed healthcare system, continue to enhance adoption of cyclodextrins throughout Europe.

U.K. Cyclodextrins in Pharma Market Insight

The U.K. cyclodextrins in pharma market is experiencing steady growth, supported by rising adoption of advanced excipients in drug formulation, strong pharmaceutical R&D activity, and increasing focus on rare disease therapies. Growing demand for improved bioavailability and drug stability is contributing to wider use of cyclodextrins in oral and injectable formulations. Furthermore, integration of innovative drug delivery technologies and expanding clinical research activities are positioning the U.K. as an important innovation hub in the cyclodextrins in pharma industry.

Germany Cyclodextrins in Pharma Market Insight

The Germany cyclodextrins in pharma market is expanding steadily due to the country’s strong pharmaceutical manufacturing base, advanced chemical expertise, and increasing adoption of high-performance excipients. Pharmaceutical companies and research institutes are increasingly utilizing cyclodextrins for improving solubility, stability, and safety of complex drug molecules. Continuous advancements in formulation science, along with strong regulatory standards and focus on high-quality drug development, are further driving market growth in Germany.

Asia-Pacific Cyclodextrins in Pharma Market Insight

The Asia-Pacific cyclodextrins in pharma market is expected to witness rapid growth, driven by expanding pharmaceutical production, increasing generic drug manufacturing, and rising investments in healthcare infrastructure across countries such as China, India, and Japan. Growing awareness of advanced drug delivery systems, rising prevalence of chronic diseases, and increasing adoption of formulation-enhancing excipients are supporting regional market expansion. In addition, growing pharmaceutical R&D activities and contract manufacturing capabilities are accelerating cyclodextrin adoption across commercial and clinical sectors.

Japan Cyclodextrins in Pharma Market Insight

The Japan cyclodextrins in pharma market is witnessing consistent growth due to rising investments in advanced drug delivery technologies, strong pharmaceutical innovation, and increasing focus on rare and chronic disease treatments. Pharmaceutical companies and research institutions are increasingly adopting cyclodextrins to enhance drug solubility and stability in complex formulations. Moreover, growing integration of high-precision formulation techniques and strong emphasis on patient safety and therapeutic efficiency are further contributing to market growth in Japan.

China Cyclodextrins in Pharma Market Insight

The China cyclodextrins in pharma market is growing rapidly, driven by expanding pharmaceutical manufacturing, rising investments in drug R&D, and increasing focus on improving drug bioavailability. Growing adoption of advanced formulation technologies across domestic pharmaceutical companies is significantly boosting demand for cyclodextrins. In addition, increasing prevalence of chronic diseases, strong government support for healthcare innovation, and rapid expansion of generic and specialty drug production are positioning China as one of the fastest-growing markets globally.

Cyclodextrins in Pharma Market Share

The cyclodextrins in pharma industry is primarily led by well-established companies, including:

• Wacker Chemie AG (Germany)
• Roquette Frères (France)
• Ashland Inc. (U.S.)
• Merck KGaA (Germany)
• Ligand Pharmaceuticals Incorporated (U.S.)
• CycloLab Cyclodextrin Research & Development Laboratory Ltd. (Hungary)
• BASF SE (Germany)
• Dow Inc. (U.S.)
• International Flavors & Fragrances Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Tokyo Chemical Industry Co., Ltd. (Japan)
• Cargill, Incorporated (U.S.)
• Shandong Xinda Biotechnology Co., Ltd. (China)
• Jiangsu Fengyuan Bioengineering Co., Ltd. (China)
• Xi’an Deli Biochemical Industry Co., Ltd. (China)
• Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. (China)
• WELDING GmbH & Co. KG (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Shandong Qianhui Biological Technology Co., Ltd. (China)

Latest Developments in Cyclodextrins in Pharma Market

• In May 2026, regulatory updates regarding adrabetadex, a cyclodextrin-based investigational therapy for Niemann-Pick disease type C, highlighted ongoing FDA review processes and the complexity of approving cyclodextrin-based rare disease treatments. The development underscores both the therapeutic potential and regulatory challenges associated with cyclodextrin-enabled drugs in advanced clinical pipelines
• In October 2025, the FDA approval of Captisol-enabled formulation (Lasix ONYU) marked a significant advancement in cyclodextrin-based drug delivery, particularly using sulfobutylether-β-cyclodextrin (SBECD) to enhance solubility and stability of injectable therapies for heart failure treatment. This development reinforced the growing regulatory acceptance of cyclodextrin excipients in parenteral drug formulations and expanded their use in hospital-based therapies
• In May 2025, a scientific review emphasized the expanding role of cyclodextrins as both pharmaceutical excipients and potential active therapeutic agents, particularly in applications such as cholesterol modulation, antiviral therapies, and rare disease treatments. The study highlighted growing R&D interest in cyclodextrin inclusion complexes and their evolving role in advanced drug delivery systems
• In April 2025, developments in orphan drug pipelines showcased increasing use of cyclodextrin-encapsulated compounds in oncology and rare disease treatment programs, reflecting rising industry focus on improving drug stability and therapeutic targeting. This shift highlights the expanding commercial relevance of cyclodextrin-based formulations in specialty pharmaceuticals
• In February 2024, scientific research highlighted major advancements in cyclodextrin-based drug delivery systems, emphasizing their increasing role in improving solubility, dissolution, and bioavailability of poorly water-soluble drugs. The study reported wider adoption of modified cyclodextrins such as HP-β-CD and SBECD in both injectable and oral formulations, reflecting strong growth in formulation science innovation

SKU-55852